Uptravi patent expiration?

Uptravi (selexipag) is protected by several patents plus regulatory exclusivities, and there isn’t a single “Uptravi patent expiry.” Expiration dates vary by country and by patent type (composition of matter, formulation, use, etc.), and regulatory exclusivity can also affect when a generic could enter.

In short:
- Core patent protection and related patents are generally expected to run into the late 2020s or early 2030s in many major markets, but exact dates depend on the jurisdiction and which patent family.
- In some places there may be additional protections (e.g., pediatric or data/regulatory exclusivity) that can delay generic entry even after patents lapse.
- A few market-specific patent terms or extensions could push certain protections into the early 2030s.

If you want a precise date, tell me the country or region you’re interested in (e.g., US, EU, UK, Japan, etc.) and whether you want:
- patent expiry date for selexipag (composition of matter or key use patents), or
- regulatory exclusivity timelines (data exclusivity, market exclusivity).

I can guide you to the exact patent families and provide the current expiry estimates for that region. I can also point you to sources (USPTO, Espacenet/Google Patents, FDA Orange Book) to look them up yourself.